Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension

References

• Galiè N, Humbert M, Vachiery JL, et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2015;2015(46):1855–1856.
   Google Scholar
• Moll M, Sardana M, Farber HW. Pulmonary hypertension, cor pulmonale, and other pulmonary vascular conditions. Scientific American Medicine. New York. 2016;1202:1–22. DOI:10.2310/7900.
   Google Scholar
• Sardana M, Moll M, Farber HW. Novel investigational therapies for treating pulmonary arterial hypertension. Expert Opin Investig Drugs. 2015 Dec 2;24(12):1571–1596.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Eng J Med. 2002;347:322–329.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galié N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–804.
   PubMed Web of Science ®Google Scholar
• Oudiz R, Schilz R, Barst R, et al. Treprostinil, a prostacyclin analogue in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126:420–427.
   PubMed Web of Science ®Google Scholar
• Girgis R, Frost A, Hill N, et al. Selective endothelin a receptor antagonism with sitaxsentan for pulmonary arterial hypertension associate with connective tissue disease. Ann Rheum Dis. 2007;66:1467–1472.
   PubMed Web of Science ®Google Scholar
• Greig SL, Scott LJ, Plosker GL. Epoprostenol (Veletri®, Caripul®): a review of its use in patients with pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2014;14:463–470.
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496–1502.
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119–2125.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest J. 2012;142:1383–1390.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest J. 2013;144:952–958.
   PubMed Web of Science ®Google Scholar
• Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension a randomized, controlled trial. Circulation. 2013;127:624–633.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533.
   PubMed Web of Science ®Google Scholar
• Asaki T, Hamamoto T, Sugiyama Y, et al. Structure–activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists. Bioorg Med Chem. 2007;15:6692–6704.
   PubMed Web of Science ®Google Scholar
• Asaki T, Kuwano K, Morrison K, et al. Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem. 2015;58:7128–7137.
   PubMed Web of Science ®Google Scholar
• Gatfield J, Menyhart K, Nayler O. Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist. Eur Respir J. 2014;44:2353.
   Google Scholar
• Kuwano K, Hashino A, Asaki T, et al. 2-{4-[(5, 6-diphenylpyrazin-2-yl)(isopropyl) amino] butoxy}-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007;322:1181–1188.
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5, 6-diphenylpyrazin-2-yl)(isopropyl) amino] butoxy}-N-(methylsulfonyl) acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form,{4-[(5, 6-diphenylpyrazin-2-yl)(isopropyl) amino] butoxy} acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther. 2008;326:691–699.
   PubMed Web of Science ®Google Scholar
• Hirata T, Narumiya S. Prostanoid receptors. Chem Rev. 2011;111:6209–6230.
   PubMed Web of Science ®Google Scholar
• Morrison K, Ernst R, Hess P, et al. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther. 2010;335:249–255.
   PubMed Web of Science ®Google Scholar
• Gatfield J, Menyhart K, Morrison K, et al. The non-prostanoid prostacyclin receptor agonist ACT-333679, the active metabolite of selexipag, is characterized by low beta-arrestin recruitment and receptor internalization activity. J Am Coll Cardiol. 2015;65:10S.
   Google Scholar
• Morrison K, Wanner D, Gatfield J, et al. Repeated oral administration of the selective prostacyclin receptor agonist selexipag does not cause tachyphylaxis in spontaneously hypertensive rats. J Am Coll Cardiol. 2015;65:10S.
   Google Scholar
• Bruderer S, Hurst N, Kaufmann P, et al. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in health subjects. Pharmacology. 2014;94:148–156.
   PubMed Web of Science ®Google Scholar
• Madabushi R, Florian J. Center for drug evaluation and research, application number: 207947Orig1s000. Clin Pharmacol Biopharm. 2014 Dec 22.
   Google Scholar
• Kaufmann P, Okubo K, Bruderer S, et al. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 2015;15:195–203.
   PubMed Web of Science ®Google Scholar
• Fischer N, Kaufmann P, Bruderer S, et al. Pharmacokinetics of selexipag in subjects with mild, moderate, or severe hepatic impairment compared with healthy subjects. Clin Ther. 2013;35(8S):e77- e78.
   Google Scholar
• Fischer N, Kaufmann P, Bruderer S, et al. Pharmacokinetics of selexipag in subjects with severe renal impairment compared with healthy subjects. Clin Ther. 2013;35(8S):e77.
   Google Scholar
• Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40:874–880.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Niglis S, Bruderer S, et al. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag, an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol. 2015;80:670–677.
   PubMed Web of Science ®Google Scholar
• Bruderer S, Okubo K, Mukai H, et al. Investigation of potential pharmacodynamic and pharmacokinetic interactions between selexipag and warfarin in healthy male subjects. Clin Ther. 2016;38(5):1228–1236.
   PubMed Web of Science ®Google Scholar